Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Ariad Pharmaceuticals
So what: Shares bounced on positive results news about ridaforolimus, which treats advanced uterine cancer. The treatment was effective, but side effects were worse than some expected.
Now what: Overall this is positive news for Ariad and considering the pullback in shares later in the day might warrant a buying opportunity. Merck
Interested in more info on Ariad Pharmaceuticals? Add it to your watchlist here by clicking here.